FindTrial
Sign In

Examination of Cognitive Function in Patients Treated With Subutex

Examination of Cognitive Function, Weight, Sexual Function in Patients Receiving Treatment With Subutex at 3 Months Without Using Opiates

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00687089
Enrollment
60
Registered
2008-05-30
Start date
2008-06-30
Completion date
2009-01-31
Last updated
2009-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opiate Addiction

Keywords

Opiates, Subutex, Buprenorphine, Patients who addicted to opiates

Brief summary

People who addicted to Heroin and other opiates suffer from a disease with approved genetic basis. It causes to a behavioral response as searching and using those drugs even though they know it causes severe damages as physiological, familiar and legal affairs. The popular treatment's goal is to clean the people from any drug. In a medical and pharmacological point of view there is no sense in this approach for all people. This point of view believes that Buprenorphine (Subutex) is a correct pharmacological treatment. The hypothesis of this research is that people using Buprenorphine have difficulties in gaining weight, in sexual and cognitive function (according to subjects' reports)

Detailed description

People who addicted to Heroin and other opiates suffer from a disease with approved genetic basis. It causes to a behavioral response as searching and using those drugs even though they know it causes severe damages as physiological, familiar and legal affairs. The popular treatment's goal is to clean the people from any drug. In a medical and pharmacological point of view there is no sense in this approach for all people. This point of view believes that Buprenorphine (Subutex) is a correct pharmacological treatment. The hypothesis of this research is that people using Buprenorphine have difficulties in gaining weight, in sexual and cognitive function (according to subjects' reports) We examine people who stopped opiates and began Buprenorphine. Every participant in the study will have two visits: the first one before receiving Buprenorphine and the second one after 3 months of receiving Buprenorphine.

Interventions

OTHERSexual, cognitive functional tests and measurement weight

Sponsors

Ebetim Clinic
CollaboratorOTHER
BeerYaakov Mental Health Center
Lead SponsorOTHER_GOV

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* People who suffer from addiction problems (opiates) * People who willing to to start Buprenorphine treatment * People who willing to cooperate with study tests and questionnaires * People aged 18 to 70

Exclusion criteria

* People who suffer from any neurocognitive problems * People who suffer from mental illnesses * People who are having legal guardian

Design outcomes

Primary

MeasureTime frame
ASI quationarry, neurocognitive computerized tests, MMSE test, Sexual function questionnaire and satisfaction questionnaireIn 2 visits during the study

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026